Tag Archives: catalysts

Bellerophon Therapeutics Inc (NASDAQ:BLPH) is all over the place at the moment. The company traded for around $.50 a share back in January, and ran up to highs of just shy of $2 a share at the beginning of this month. At the end of last week,...

Bellerophon Therapeutics Inc (NASDAQ:BLPH) is a real runner this week, with the company currently trading around $1.50 a share – a close to 40% gain on its weekly open and a more than 65% premium on last week’s mid week pricing. At first...

At the beginning of February, we published this article on Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX), noting the upside momentum seen during the period running up to our coverage, and attempting to ascertain whether this action was a one-off...

Matinas BioPharma Holdings Inc (OTCMKTS:MTNB) put out a business outlook at the end of January, and alongside the outlook, gave markets a number of milestones to keep an eye on across the coming twelve months. This is one we’ve looked at...

Towards the end of January, we highlighted Cellectar Biosciences Inc (NASDAQ:CLRB) as being a company to keep an eye on across the next six to eight weeks. The company had a number of potential catalysts that – at then-time of writing –...

Idera Pharmaceuticals Inc (NASDAQ:IDRA) is one of those stocks that starts off looking incredibly promising, and then over time struggles to maintain investor interest in its operations, and as a result, gradually declines in line with the...

Delcath Systems, Inc. (NASDAQ:DCTH) has had a pretty rough start to the year, and is currently trading around 53% off its annual open. The decline comes about on the back of no real negative catalysts, aside from – perhaps – the unmet expectations...

Cellectar Biosciences Inc (NASDAQ:CLRB) just announced that it has had an additional patent granted by the United States Patent and Trademark Office (USPTO) relating to the its two lead assets, CLR 131 and CLR 125. The release was relatively...

Heat Biologics Inc (NASDAQ:HTBX) struggled during the final quarter of 2016, as the company put out disappointing results from its lead bladder cancer trial. Sentiment remained pretty negative towards the close of the year, but as 2017 has...

Biocept Inc (NASDAQ:BIOC) gained more than 77% during Tuesday’s session this week, and is up more than 100% on last week’s close, on news that the company has picked up a fresh round of insurance coverage for its lead biopsy product....

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter